Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Prognostic Value of HLA Evolutionary Divergence in AML Patients Treated with Venetoclax and Hypomethylating Drugs

Blood (2024) 144 (Supplement 1): 6086.

https://doi.org/10.1182/blood-2024-198869

Published: 2024

Journal Articles

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2024-207060

Published: 2024

Journal Articles

Association of Glasdegib + Low-Dose Cytarabine (AraC)) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients

Ilaria Tanasi, Antonella Bruzzese, Ambra Di Veroli, Calogero Vetro, Lorenzo Rizzo, Giulia De Luca, Federica Pilo, Stefano Pravato, Alfredo Molteni, Carmela Gurrieri, Prassede Salutari, Giuseppe Alberto Palumbo, Ernesto Vigna, Massimiliano Bonifacio, Marta Riva, Roberto Latagliata

Blood (2024) 144 (Supplement 1): 6041.

https://doi.org/10.1182/blood-2024-206787

Published: 2024

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Alessandro Bosi, Bruno Fattizzo, Lorenzo Rizzo, Silvia Ferrari, Federico Lussana, Lorenza Maria Borin, Andrea Castelli, Paola Bianchi, Wilma Barcellini, Roberto Cairoli, Alfredo Molteni, Marta Riva

Blood (2022) 140 (Supplement 1): 6925–6926.

https://doi.org/10.1182/blood-2022-157430

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Luspatercept in Combination with Recombinant-Erythropoietin in MDS RS Patients: Stimulating Early and Late Erythropoiesis

Francesco Versino, Marta Bortolotti, Beatrice Ferrari, Lorenzo Rizzo, Federico Mazzon, Marta Riva, Paola Bianchi, Wilma Barcellini, Bruno Fattizzo

Blood (2022) 140 (Supplement 1): 12323–12324.

https://doi.org/10.1182/blood-2022-158279

Published: 2022

Journal Articles

Luspatercept in MDS with Ring Sideroblasts: A Real-Life Multicenter Experience from a Named Patient Program

Marta Riva, Bruno Fattizzo, Lorenzo Rizzo, Federico Mazzon, Juri Alessandro Giannotta, Wilma Barcellini, Roberto Cairoli

Blood (2021) 138 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2021-153179

Published: 2021

Journal Articles

Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Marta Riva, Lorenzo Rizzo, MD, Valentina Mancini, MD, Rosa Greco, MD, Giambattista Bertani, MD, Elisa Zucchetti, MD, Elisa Diral, MD, Michele Nichelatti, PhD, Silvio Marco Veronese, Giovanni Grillo, MD, Roberto Cairoli

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141987

Published: 2020

Journal Articles

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Lorenzo Rizzo, Michelina Santopietro, MD, Gianluca Sfaciotti, MD, Marco Brunori, MD, Luisa Cardarelli, MD, Giovanna Palumbo, MD, Daniela De Benedittis, MD, Martina Di Palma, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Tiziana Di Pippo, Fiorina Giona, MD

Blood (2019) 134 (Supplement_1): 1041.

https://doi.org/10.1182/blood-2019-129707

Published: 2019

Journal Articles

Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome

Francesco Malaspina, MD, Maria Caterina Putti, MD, Michelina Santopietro, MD, Saverio Ladogana, MD, Rosamaria Mura, MD, Roberta Burnelli, MD, Nadia Vacca, MD, Lorenzo Rizzo, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Andrea Biondi, Franco Locatelli, Giuseppe Saglio, Robin Foà, MD, Fiorina Giona, MD

Blood (2018) 132 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2018-99-118030

Published: 2018

Journal Articles

Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice

Emilia Scalzulli, MD, Matteo Molica, MD, Alunni Fegatelli Danilo, Lorenzo Rizzo, Roberto Latagliata, Robin Foà, MD, Massimo Breccia, MD

Blood (2018) 132 (Supplement 1): 5518.

https://doi.org/10.1182/blood-2018-99-114880

Published: 2018

Journal Articles

Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice

Matteo Molica, MD, Emilia Scalzulli, MD, Alunni Fegatelli Danilo, Roberto Latagliata, Gioia Colafigli, MD, Lorenzo Rizzo, Daniela Diverio, Robin Foà, MD, Massimo Breccia, MD

Blood (2018) 132 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2018-99-116486

Published: 2018

Journal Articles

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, MD, Alessandra Iurlo, MD, Gabriele Gugliotta, MD PhD, Alessia Tieghi, MD, Lucia Canafoglia, MD, Raffaele Palmieri, MD, Crescenza Pasciolla, MD, Nicola Vianelli, MD, Riccardo Ragionieri, Erminia Rinaldi, MD, Emilio Usala, MD, Giorgio La Nasa, MD, Alessandra Perra, MD, Giuseppe Tagariello, MD, Nilla Maschio, MD, Emma Cacciola, PhD, Rossella Rosaria Cacciola, PhD, Micaela Bergamaschi, MD, Anna Da Col, MD, Angela Rago, MD, Lorenzo Rizzo, MD, Francesco Spina, MD, Daniele Cattaneo, MD, Daniela Lambertenghi, MD, Aniello Casoria, MD, Maria Langella, Maria Luigia Randi, MD, Elisabetta Cosi, MD, Monica Crugnola, MD, Elena Masselli, MD, Paola Ranalli, MD, Giovanni Garozzo, MD, Katia Codeluppi, Oreste Villani, MD, Grazia Ferrara, Cristina Santoro, MD, Potito Rosario Scalzulli, MD, Manlio Ricciotti, MD, Viviana Appolloni, MD, Anna Candoni, MD, Annalisa Luraschi, MD, Rupoli Serena, MD, Mauro DI Ianni, MD, Giovanni Caocci, MD, Francesco Lanza, MD, Nicola Orofino, MD, Elisa Rumi, MD, Alfredo Dragani, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Umberto Santoro, Alessandro M. Vannucchi, MD PhD

Blood (2016) 128 (22): 5472.

https://doi.org/10.1182/blood.V128.22.5472.5472

Published: 2016

NARROW

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Prognostic Value of HLA Evolutionary Divergence in AML Patients Treated with Venetoclax and Hypomethylating Drugs

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Association of Glasdegib + Low-Dose Cytarabine (AraC)) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Luspatercept in Combination with Recombinant-Erythropoietin in MDS RS Patients: Stimulating Early and Late Erythropoiesis

Luspatercept in MDS with Ring Sideroblasts: A Real-Life Multicenter Experience from a Named Patient Program

Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Specific Guidelines Including Multidisciplinary Approach Is Critical of Management of Langerhans Cell Histiocytosis in Adults

Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome

Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice

Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only